DAX24.240 +0,1%Est505.675 +0,1%MSCI World4.343 -0,1%Top 10 Crypto14,88 -2,1%Nas23.205 +1,2%Bitcoin96.053 +0,6%Euro1,1625 ±0,0%Öl65,69 -0,4%Gold4.112 -0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Beyond Meat A2N7XQ TKMS thyssenkrupp Marine Systems TKMS00 Rheinmetall 703000 NVIDIA 918422 Porsche vz. PAG911 RENK RENK73 D-Wave Quantum A3DSV9 DroneShield A2DMAA Lufthansa 823212 Tesla A1CX3T Deutsche Telekom 555750 SAP 716460 Intel 855681 Siemens Energy ENER6Y AMD (Advanced Micro Devices) 863186
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Handelsstreit im Blick: DAX geht im Plus ins Wochenende -- US-Börsen schließen stärker -- Intel: Starke Zahlen -- HENSOLDT, Lufthansa, DroneShield, SuperMicro, TKMS, Beyond Meat, Dow im Fokus
Top News
Bitcoin, Dogecoin, Ethereum & Co. am Mittag Bitcoin, Dogecoin, Ethereum & Co. am Mittag
Barbell-Strategie: Was Anleger über die "Hantelstrategie" wissen müssen Barbell-Strategie: Was Anleger über die "Hantelstrategie" wissen müssen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Inhibikase Therapeutics Aktie

Kaufen
Verkaufen
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2QAMK

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS45719W1062

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIKT

Inhibikase Therapeutics Aktien News

DatumMeistgelesen
PR NewswireHuawei Europe Enterprise Roadshow 2025 in Hamburg: Maßgeschneiderte Branchenlösungen für die digitale Transformation
PR NewswireSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)
ZacksInhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
PR NewswireInhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib
PR NewswireInhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
PR NewswireInhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib
PR NewswireInhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro
PR NewswireInhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
PR NewswireInhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023
PR NewswireInhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements
PR NewswireInhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
PR NewswireInhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study
PR NewswireInhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease
PR NewswireInhibikase Therapeutics to Present at the LD Micro Invitational XIII
PR NewswireInhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
finanzen.netInhibikase Therapeutics: Bilanz zum abgelaufenen Quartal
PR NewswireInhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
finanzen.netAusblick: Inhibikase Therapeutics präsentiert Bilanzzahlen zum jüngsten Jahresviertel
PR NewswireInhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023
PR NewswireInhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
PR NewswireInhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease
PR NewswireInhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase
finanzen.netInhibikase Therapeutics informierte über die jüngsten Quartalsergebnisse
PR NewswireInhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity
PR NewswireInhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023
PR NewswireInhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders
PR NewswireInhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023
PR NewswireInhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro
PR NewswireInhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy
PR NewswireInhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit
PR NewswireInhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders
PR NewswireInhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease
PR NewswireInhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro
PR NewswireInhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs
PR NewswireInhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
finanzen.netInhibikase Therapeutics: So schnitt der Konzern im vergangenen Quartal ab
PR NewswireInhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
PR NewswireInhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
PR NewswireInhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs

Inhibikase Therapeutics News

Inhibikase Therapeutics News: auf dieser Seite finden Sie alle Inhibikase Therapeutics News und Nachrichten zur Inhibikase Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Inhibikase Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Inhibikase Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.